---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-104587"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2025-08-07T23:59:59+00:00"
generated_at: "2026-05-17T17:50:31.979393+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma Q2 net loss $21.2M; cash $148.3M; Phase 2 interim analysis webinar Sept 10

## Summary
- Net loss $21.2M for Q2 2025 vs $1.2M in Q2 2024, due to prior-year $16.2M tax benefit from NOL sale.
- Cash, equivalents, and marketable securities $148.3M as of June 30, 2025, expected runway to end of 2026.
- R&D expenses $18.4M (up 26% YoY) driven by contractual research costs for rezatapopt program.
- Investor webinar Sept 10 to review Phase 2 PYNNACLE interim data; ~65 patients, ~45% ovarian cancer.

## SEC filing metadata
- accession: 0000950170-25-104587
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2025-08-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000095017025104587/0000950170-25-104587-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000095017025104587/pmvp-20250807.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-104587
- JSON: https://secwatch.observer/filing/0000950170-25-104587.json
- Plain text: https://secwatch.observer/filing/0000950170-25-104587.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.